Stage A Heart Failure Is Not Adequately Recognized in US Adults: Analysis of the National Health and Nutrition Examination Surveys, 2007-2010

Lara C. Kovell1*, Stephen P. Juraschek2, Stuart D. Russell1

1 Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 2 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America

* lkovell1@jhmi.edu

Abstract

Background
Stage A heart failure (HF) is defined as people without HF symptoms or structural heart disease, but with predisposing conditions for HF. This classification is used to identify high risk patients to prevent progression to symptomatic HF. While guidelines exist for managing HF risk factors, achievement of treatment goals in the United States (US) population is unknown.

Methods
We examined all adults with Stage A HF (≥20 years, N =4,470) in the National Health and Nutrition Examination Surveys (NHANES) 2007-2010, a nationally representative sample. Stage A HF was defined by coronary heart disease (CHD), hypertension, diabetes mellitus, or chronic kidney disease. We evaluated whether nationally accepted guidelines for risk factor control were achieved in Stage A patients, including sodium intake, body mass index, hemoglobin A1c (HbA1c), cholesterol, and blood pressure (BP). Pharmacologic interventions and socioeconomic factors associated with guideline compliance were also assessed.

Results
Over 75 million people, or 1 in 3 US adults, have Stage A HF. The mean age of the Stage A population was 56.9 years and 51.5% were women. Seventy-two percent consume ≥2g sodium/day and 49.2% are obese. Of those with CHD, 58.6% were on a statin and 51.8% were on a beta-blocker. In people with diabetes, 43.6% had HbA1c ≥7%, with Mexican Americans more likely to have HbA1c ≥7%. Of those with hypertension, 30.8% had a systolic BP ≥140 or diastolic BP ≥90 mm Hg. Having health insurance was associated with controlled blood pressure, both in those with hypertension and diabetes. In CHD patients,
Conclusions

One-third of the US adult population has Stage A HF. Prevention efforts should focus on those with poorly controlled comorbid disease.

Introduction

Over 5.1 million Americans have heart failure (HF), a devastating disease associated with high morbidity, mortality, and cost.[1] Despite advances in therapies, only 50% of patients survive 5 years after diagnosis with HF.[2] The estimated cost of HF was $32 billion in 2013 with projections predicting $70 billion by 2030.[1,3] In an attempt to encourage prevention and identify people at risk for HF, the American College of Cardiology (ACC)/American Heart Association (AHA) defined Stage A HF as people without HF symptoms but with related comorbid diseases conferring high risk for developing HF, such as coronary heart disease (CHD), diabetes mellitus, hypertension, or chronic kidney disease.[4] However, adequate control of risk factors among US adults with Stage A HF is unknown.

While prevention has been the focus of CHD and diabetes for decades, HF prevention lags behind with new estimates suggesting 1 in 33 people will have HF by 2030.[3] HF prevention involves adjusting lifestyle factors such as salt intake and weight, risk factor control (body mass index, blood pressure, cholesterol, blood sugar), and the use of medications proven to curb progression to HF.[5–16] While aggressive risk factor control is recommended in Stage A HF to prevent HF progression, the degree of control and rates of therapy in this population, along with the factors associated with risk reduction, have never been determined in the US population.

The purpose of the present study was to characterize US adults with Stage A HF in a nationally representative population, using the National Health and Nutrition Examination Survey (NHANES) conducted from 2007–2010. Additionally, we examined the achievement of risk factor control, the use of pharmacologic interventions with known efficacy in delaying HF onset, and the demographic and socioeconomic variables associated with medication use and poor control of risk factors.

Methods

Study Population

The NHANES are cross-sectional studies conducted by the National Center for Health Statistics (NCHS). The study population was recruited via mobile examination centers, which visit US communities selected using a complex, multistage sampling design to represent the age, sex, and racial/ethnic distribution of the US. In this study, we used the interviews, physical examinations, and laboratory measurements gathered by the continuous NHANES surveys (2007–2010) from participants age 20 years and older. These studies were approved by the NCHS Research Ethics Review Board and informed consent was obtained from all participants.[17]

Stage A Heart Failure

Stage A HF was defined among participants without a diagnosis of heart failure as any of the following self-reported conditions that were identified by a doctor or other health professional:
CHD/myocardial infarction (MI), diabetes mellitus, hypertension, or chronic kidney disease. We used self-report rather than laboratory or anthropometric measures because these represented a population for which a physician or health professional had identified a Stage A HF condition.

Heart Failure Risk Factors

We examined risk factors known to be associated with the progression of HF that also had well-established treatment guidelines. Dietary sodium intake was determined via 24-hour dietary recall interviews, initially administered in-person then followed by a telephone call 3–10 days later. Sodium intake was dichotomized as <2000 mg/d and ≥2000 mg/d.[18] Body mass index (BMI) was determined by measuring standing height and weight and stratified by obese (BMI ≥30 kg/m²) or not obese (BMI <30 kg/m²). Low density lipoprotein cholesterol (LDL) was estimated in a subsample of NHANES participants using the Friedewald equation[19] and dichotomized according to ATP III guidelines (<100 mg/dL vs. ≥100 mg/dL) with an alternative guideline cutpoint of 70 mg/dL as well.[20] Hemoglobin A1c was dichotomized as <7% or ≥7%. Control of blood pressure was determined by systolic blood pressure (SBP) <140 mm Hg and diastolic blood pressure (DBP) <90 mm Hg among persons with a prior diagnosis of hypertension.[21] We examined two targets for blood pressure control in participants with a prior diagnosis of diabetes or chronic kidney disease based on the more stringent JNC VII (SBP <130 and DBP <80 mm Hg) or the 2014 Hypertension guidelines (SBP <140 and DBP <90 mm Hg). [21,22] Smoking status was examined in categories of never, former, or current. Alcohol use was examined in categories of never, former, non-excessive current, or excessive current.[23]

Demographic and Socioeconomic Factors

Age, sex, and race/ethnicity information were collected from all participants. Race/ethnicity was characterized as non-Hispanic white, non-Hispanic black, Mexican American, Hispanic, and Other.[17] Socioeconomic factors examined were family income, health insurance, and education level. Self-reported annual family income data was collected from study participants and dichotomized as ≥$20,000 or <$20,000. Health insurance coverage was based on an affirmative response to the following question: “Are you covered by health insurance or some other kind of health care plan?” Education level was ascertained with the question “What is the highest grade or level of school you have received?” Educational attainment was subsequently dichotomized as ≥ some college or < some college.

Medication Use

Participants were asked to bring their medication bottles to the examination center. Medications used in the past 30 days were recorded by NHANES staff. In this study, we grouped medications in the following three categories: angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor antagonists (ARBs), HMG-CoA reductase inhibitors (statins), or beta-adrenergic blocking agents (beta-blockers).

Statistical Analyses

All analyses were performed using the sample weights, primary sampling units, and strata in concordance with NCHS recommendations to account for the NHANES complex sampling design.[24] Standard errors were determined for all metrics using the Taylor series (linearization) method. Prevalence ratios were estimated via Poisson regression, which provides a more accurate estimate of prevalence than logistic regression.[25] Analyses were performed with Stata 11.1 (StataCorp LP, College Station, TX).
Characteristics of NHANES participants with Stage A HF were determined using weighted means or prevalence estimates along with standard errors. We also evaluated the prevalence and number of US adults with Stage A HF and achievement of risk factor targets. Poisson regression and prevalence ratios were used to examine the association between family income ≥$20,000, health insurance, or education ≥ some college and the achievement of recommended risk factor targets. Poisson models were nested as follows. Model 1 was adjusted for age, sex, and race/ethnicity, while Model 2 was adjusted for Model 1 and family income, health insurance status, and education level. We also explored demographic factors associated with meeting risk factor targets, adjusting for Model 2 covariates and using forest plots.

In order to maintain consistency with the CHD/MI category, the estimates for LDL were made using the standard 2-year weights rather than the recommended subsample weights. A sensitivity analysis evaluating the LDL using the recommended weighting scheme yielded virtually identical results.

Results
Table 1 shows recommendations for lifestyle modifications and treatment targets for Stage A HF, based on guidelines available during the survey period 2007–2010 as well as current guidelines.[20–22, 26–32] There were 11,730 adults, age 20 and older, surveyed and examined at the mobile examination center in NHANES 2007–2010. Population characteristics are in Table 2. The number of US adults in 2007–2010 with Stage A HF was over 75 million, corresponding to 33% of the US adult population.[33] Examination of modifiable risk factors found that sodium intake was >2,000 mg of salt per day in 72% of these participants. Nearly half were obese with an additional 32% overweight. Among adults with CHD or prior MI, 36.3% had LDL ≥100 mg/dL and 78.5% had LDL ≥70 mg/dL. In Stage A HF patients with diabetes, the prevalence of HbA1c >7% was 44%. Furthermore, 49.2% had a SBP ≥130 or DBP ≥80 mm Hg while 26.9% had a SBP ≥140 or DBP ≥90 mm Hg. Of those with hypertension, 30.8% had a SBP ≥140 or DBP ≥90 mm Hg. In those with kidney disease, 40.0% had SBP ≥130 or DBP ≥80 mm Hg while 18.2% had SBP ≥140 or DBP ≥90 mm Hg. With regards to medications, in those with CHD/MI, only 45.9% were taking ACE inhibitors/ARBs, 58.6% were taking statins, and 51.8% were taking beta-blockers. ACE inhibitor/ARB use was also determined in participants with diabetes, of whom 50.8% were taking this class of medications.

Fig 1 shows a stratified analysis of risk factors by age, sex, and race. Sodium intake was lower with increasing age. Women more commonly consumed <2,000 mg of sodium compared with men (PR: 0.83; 95% CI: 0.80, 0.86; P<0.001). With regard to race, non-Hispanic white participants were the most likely to consume ≥2,000 mg of sodium. BMI was also lower with age, while women and non-Hispanic blacks were more likely to have a BMI ≥30, with PR 1.11 (95% CI: 1.01, 1.21; P = 0.03) and 1.16 (CI 1.07, 1.25; P<0.001), respectively.

For LDL in those with CHD or a prior MI, there was a trend towards better control in participants >30 years (Fig 1). In US adults with a diagnosis of diabetes, Mexican-Americans were more likely to have HbA1c ≥7%. In the same group with diabetes, non-Hispanic black adults had a PR of 1.54 (95% CI: 1.20, 1.97) for SBP ≥140 mm Hg or DBP ≥90 mm Hg and a PR of 1.30 (95% CI: 1.10, 1.53) for SBP ≥130 mm Hg or DBP ≥80 mm Hg (S1 Fig). Uncontrolled hypertension, defined by SBP ≥140 mm Hg or DBP ≥90 mm Hg, was more common in participants aged 50–<70 years and ≥70 years. Non-Hispanic black participants also had a higher prevalence of uncontrolled BP (PR 1.42; 95% CI: 1.25, 1.62). Among participants with kidney disease, women (PR: 1.63; 95% CI: 1.05, 2.54), non-Hispanic blacks (PR: 2.34; 95% CI: 1.21, 4.51), and Mexican Americans (PR: 1.88; 95% CI: 1.11, 3.17) were associated with SBP ≥140 mm Hg or DBP ≥90 mm Hg. When using the JNC VII blood pressure goals, age ≥70 years
### Table 1. Recommendations for Treatment Targets in Stage A Heart Failure.

| Lifestyle Factors | Target/Goal | Guideline |
|-------------------|-------------|-----------|
| Daily sodium intake | < 1500 mg/d* | AHA, HHS, USDA |
|                   | < 2300 mg/d† |           |
| No target         |             | IOM       |
| Weight            | BMI < 30 kg/m² | ACC/AHA   |
|                   | BMI < 25 kg/m²‡ | ACC/AHA   |
| Tobacco use       | Advise about hazards, encourage to quit | ACC/AHA   |
| Alcohol use       | Counsel about intake | ACC/AHA   |
| Exercise          | 150 minutes per week, moderate intensity | CDC, ACC/AHA |

### Control of Co-morbid Disease

#### Diabetes
- Glycemia: HbA1c < 7.0% | ADA
- Blood pressure: SBP<140 mm Hg, DBP<90 mm Hg | ADA 2014, 2014 Hypertension guidelines
- SBP<130 mm Hg, DBP<80 mm Hg | ADA 2013, JNC VII
- Lipid management: LDL<100 mg/dl, LDL<70 mg/dl‡ | ADA 2014, NQF
- ACE inhibitor/ARB: Start if Albumin:creatinine ratio ≥30 mg/g | ADA

#### Hypertension
- Blood pressure: SBP<150 mm Hg, DBP < 90 if age ≥ 60 years | 2014 Hypertension guidelines
- SBP<140 mm Hg, DBP<90 mm Hg if age < 60 years | 2014 Hypertension guidelines
- SBP<140 mm Hg, DBP<90 mm Hg | JNC VII

#### CHD/MI
- Lipid management: LDL<100 mg/dl, LDL<70 mg/dl‡ | ATP III
- High intensity statin if age < 75 years | ACC/AHA 2013
- ACE inhibitor/ARB: Consider for all patients | ACC/AHA
- Beta-blocker: Start and continue indefinitely | ACC/AHA
- Statin: To achieve goals as above | ACC/AHA

#### CKD
- Blood pressure: SBP<140 mm Hg, DBP<90 mm Hg | 2014 Hypertension guidelines
- SBP<130 mm Hg, DBP<80 mm Hg | JNC VII, NKF
- ACE inhibitor/ARB: Start if Protein:creatinine ratio ≥200 mg/g | NKF

---

* ≥51 years old, African American, HTN, DM, CKD
† General population
‡ Ideal target

Abbreviations: BMI: body mass index; AHA: American Heart Association; HHS: US Department of Health and Human Resources; USDA: US Department of Agriculture; IOM: institute of medicine; BMI: body mass index; ACC: American College of Cardiology Foundation; CDC: Centers for Disease Control; HbA1c: hemoglobin A1c; ADA: American Diabetes Association; NQF: National Quality Forum; SBP: systolic blood pressure; DBP: diastolic blood pressure; JNC: Joint National Committee; CHD: coronary heart disease; MI: myocardial infarction; LDL: low-density lipoprotein cholesterol; ATP: Adult Treatment Panel; ACE, angiotensin converting enzyme; ARB, angiotensin receptor antagonists; Statin, HMG-CoA reductase inhibitors; Beta-blocker, beta-adrenergic blocking agent; CKD: chronic kidney disease; NKF: National Kidney Foundation

doi:10.1371/journal.pone.0132228.001
and non-Hispanic blacks (PR 1.70; 95% CI: 1.17, 2.48) were associated with having a SBP/C21 130 mm Hg or DBP/C21 80 mm Hg.

In US adults with Stage A HF, after adjustment for demographic and socioeconomic factors, income/C21 $20,000 was associated with a sodium intake/C21 2,000 mg while insurance status and education level was not associated with salt intake (Table 4). The prevalence of BMI/C21 30 kg/m2 was higher in those with health insurance (PR 1.13, P = 0.05) and lower in those with some college education (PR 0.90; P = 0.04). In those with prior CHD/MI, income/C21 $20,000/year and health insurance were inversely associated with LDL/C21 100 mg/dL with PRs of 0.58 (P = 0.03) and 0.56 (P = 0.03), respectively. Having health insurance was also inversely correlated with

Table 2. Population Characteristics of US Adults ≥20 With and Without Stage A HF, 2007–2010.

| Weighted mean (SE) or % | No HF | Stage A HF | HF | Overall |
|-------------------------|-------|------------|----|---------|
| Age, years              | 41.3 (0.3) | 56.9 (0.33) | 66.0 (0.7) | 46.9 (0.3) |
| Male, %                 | 47.9 | 48.5 | 53.4 | 48.2 |
| Race/Ethnicity, %       |       |       |     |        |
| Non-Hispanic white      | 67.5 | 70.9 | 69.0 | 68.7 |
| Non-Hispanic black      | 10.0 | 13.5 | 17.1 | 11.3 |
| Mexican American        | 9.9 | 5.9 | 3.3 | 8.5 |
| Hispanic                | 5.5 | 4.0 | 3.6 | 5.0 |
| Other                   | 7.0 | 5.6 | 7.0 | 6.6 |
| Annual family income ≥$20,000, % | 83.0 | 80.3 | 72.3 | 81.9 |
| Highest level of education ≥high school, % | 59.1 | 52.4 | 39.2 | 56.4 |
| Participant possesses health insurance, % | 75.6 | 87.8 | 94.0 | 79.9 |
| Body Mass Index (kg/m²) | 27.4 (0.1) | 30.9 (0.1) | 31.9 (0.5) | 28.6 (0.1) |
| Hemoglobin A1c, %       | 5.4 (0.01) | 6.0 (0.03) | 6.4 (0.1) | 5.6 (0.02) |
| Systolic blood pressure, mm Hg | 117.1 (0.3) | 124.9 (0.3) | 126.1 (1.3) | 121.4 (0.3) |
| Diastolic blood pressure, mm Hg | 69.8 (0.4) | 71.0 (0.4) | 64.2 (0.9) | 70.1 (0.4) |
| High density lipoprotein cholesterol, mg/dL | 53.6 (0.4) | 50.7 (0.4) | 48.2 (1.1) | 52.6 (0.3) |
| Low density lipoprotein cholesterol, mg/dL | 118.2 (0.8) | 112.2 (1.0) | 105.9 (4.5) | 116.0 (0.7) |
| Estimated GFR (mL/min per 1.73m²) | 100.8 (0.6) | 85.0 (0.6) | 69.4 (1.9) | 95.0 (0.5) |
| MI/CHD, %               | 0 | 11.2 | 56.7 | 4.9 |
| Diabetes, %             | 0 | 25.0 | 41.3 | 9.1 |
| Hypertension, %         | 0 | 87.6 | 75.6 | 30.3 |
| Kidney Disease, %       | 0 | 5.0 | 16.8 | 2.0 |
| Sodium intake, mg       | 3,653 (33) | 3,398 (48) | 2,887 (98) | 3,552 (29) |
| Smoking status, %       |       |       |     |        |
| Never                   | 56.9 | 49.9 | 40.1 | 54.3 |
| Former                  | 19.7 | 31.9 | 42.2 | 24.2 |
| Current                 | 23.4 | 18.1 | 17.7 | 21.5 |
| Alcohol use, %          |       |       |     |        |
| Never                   | 10.0 | 13.4 | 16.0 | 11.3 |
| Former                  | 18.8 | 29.8 | 44.1 | 23.0 |
| Non-excessive current   | 35.7 | 36.3 | 29.7 | 35.8 |
| Excessive current       | 35.5 | 20.4 | 10.2 | 30.0 |

Abbreviations: HF, heart failure; GFR, glomerular filtration rate; MI, myocardial infarction; CHD, coronary heart disease

doi:10.1371/journal.pone.0132228.t002
Table 3. Control of Risk Factors and Medication Use in US Adults ≥20 with Stage A HF.

|                                      | Weighted No. (in millions) | Proportion of Weighted No. (%) | US prevalence* |
|--------------------------------------|----------------------------|--------------------------------|----------------|
| All persons with Stage A HF          | 75.3                       | 33.35 (0.76)                   |                |
| Sodium intake (mg/d)                 |                            |                                |                |
| <2000                                | 13.4                       | 19.8                           |                |
| ≥2000                                | 54.2                       | 80.2                           |                |
| Body Mass Index (kg/m²)              |                            |                                |                |
| <25                                  | 12.9                       | 18.5                           |                |
| 25–29.9                              | 22.4                       | 32.3                           |                |
| ≥30                                  | 34.2                       | 49.2                           |                |
| Persons with CHD/MI                  | 7.74                       | 3.66 (0.21)                    |                |
| Cholesterol control                  |                            |                                |                |
| LDL < 100 mg/dl†                     | 2.45                       | 63.7                           |                |
| LDL ≥ 100 mg/dl†                     | 1.39                       | 36.3                           |                |
| LDL < 70 mg/dl†                      | 0.83                       | 21.5                           |                |
| LDL ≥ 70 mg/dl†                      | 3.02                       | 78.5                           |                |
| ACE inhibitor/ARB use                |                            |                                |                |
| Yes                                  | 3.55                       | 45.9                           |                |
| No                                   | 4.19                       | 54.1                           |                |
| Statin use                           |                            |                                |                |
| Yes                                  | 4.54                       | 58.6                           |                |
| No                                   | 3.21                       | 41.4                           |                |
| Beta-blocker use                     |                            |                                |                |
| Yes                                  | 4.01                       | 51.8                           |                |
| No                                   | 3.73                       | 48.2                           |                |
| Persons with Diabetes                | 17.6                       | 8.33 (0.39)                    |                |
| Glycemic control                     |                            |                                |                |
| HbA1c <7                             | 9.09                       | 51.6                           |                |
| HbA1c ≥7                             | 7.69                       | 43.6                           |                |
| Blood pressure control (JNC VII)     |                            |                                |                |
| SBP <130 & DBP <80 mm Hg             | 8.95                       | 50.8                           |                |
| SBP ≥130 or DBP ≥80 mm Hg            | 8.68                       | 49.2                           |                |
| Blood pressure control (2014 Hypertension guidelines) | | | |
| SBP <140 & DBP <90 mm Hg             | 12.5                       | 73.1                           |                |
| SBP ≥140 or DBP ≥90 mm Hg            | 4.6                        | 26.9                           |                |
| ACE inhibitor/ARB use                |                            |                                |                |
| Yes                                  | 8.95                       | 50.8                           |                |
| No                                   | 8.68                       | 49.2                           |                |
| Persons with Hypertension            | 61.9                       | 29.21 (0.77)                   |                |
| SBP <140 & DBP <90 mm Hg             | 41.1                       | 69.2                           |                |
| SBP ≥140 or DBP ≥90 mm Hg            | 18.3                       | 30.8                           |                |
| Persons with Kidney Disease          | 3.53                       | 1.67 (0.13)                    |                |
| Blood pressure control (JNC VII)     |                            |                                |                |
| SBP <130 & DBP <80 mm Hg             | 2.1                        | 60.0                           |                |
| SBP ≥130 or DBP ≥80 mm Hg            | 1.4                        | 40.0                           |                |
| Blood pressure control (2014 Hypertension guidelines) | | | |
| SBP <140 & DBP <90 mm Hg             | 2.7                        | 81.8                           |                |

(Continued)
uncontrolled blood pressure with PR 0.70 (P = 0.002). Table 5 shows socioeconomic factors that are associated with appropriate treatment for US adults with Stage A HF. Income ≥$20,000/year was positively associated with statin use among US adults with prior CHD/MI. Health insurance was associated with beta-blocker use in the same population. In contrast, education was not associated with medication use.

Discussion

Based on a survey of US adults, one in three adults had been told by a health professional that they have a condition consistent with Stage A HF, representing approximately 75 million people. Similarly, in patients with known CHD or prior MI, only half are on medications shown to be beneficial for secondary prevention and to prevent progression to later stage HF. While having health insurance was inversely associated with uncontrolled LDL and BP, education level was not associated with improved control of any modifiable HF risk factors except BMI.

Table 3. (Continued)

| Weighted No. (in millions) | Proportion of Weighted No. (%) | US prevalence* |
|---------------------------|--------------------------------|----------------|
| SBP ≥ 140 or DBP ≥ 90 mm Hg | 0.6                           | 18.2          |

*The US total population is limited to adults age 20 years and older with Stage A HF who do not have a clinical diagnosis of HF

1 Note LDL only measured in subgroup of total population, proportions are based on the total of individuals with measured values

Abbreviations: HF, heart failure; CHD, coronary heart disease; MI, myocardial infarction; LDL, low density lipoprotein cholesterol; HbA1c, hemoglobin A1c; SBP, systolic blood pressure; DBP, diastolic blood pressure; ACE, angiotensin converting enzyme; ARB, angiotensin receptor antagonists; Statin, HMG-CoA reductase inhibitors; Beta-blocker, beta-adrenergic blocking agent

doi:10.1371/journal.pone.0132228.003

Fig 1. Demographic factors (age, sex, race/ethnicity) associated with poor risk factor control in US adults with stage A heart failure (HF). Factors examined were (A) sodium intake ≥2,000 mg/d in any adult with stage A HF, (B) body mass index ≥30 kg/m² in any adult with stage A HF, (C) low density lipoprotein cholesterol (LDL) ≥100 mg/dL (≥2.59 mmol/L) in participants with a history of coronary heart disease or myocardial infarction, (D) LDL ≥70 mg/dL (≥1.81 mmol/L) in participants with a history of diabetes, (E) hemoglobin A1c ≥7% in participants with a history of diabetes, (F) systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg in participants with diabetes, (G) SBP ≥140 mm Hg or DBP ≥90 mm Hg in participants with hypertension, and (H) SBP ≥140 mm Hg or DBP ≥90 mm Hg in participants with kidney disease. Diamonds represent the reference groups. Circles represent the prevalence ratios. Horizontal capped lines represent the 95% confidence interval.

doi:10.1371/journal.pone.0132228.g001
Participants with lower income had higher cholesterol and were less likely to be on a statin, though reported lower sodium intake than higher income participants.

The ACC/AHA stages of HF characterize the progression of HF from pre-clinical to end-stage disease. For Stage A HF, the current guidelines recommend counseling, risk factor reduction, and control of concurrent diseases. Hypertension is the most common risk factor for HF, shown to have a population attributable risk of 39% in men and 59% in women.[34],[35] Men with hypertension have a higher lifetime risk of developing HF, compared to normotensive men.[36] Despite being diagnosed with hypertension, over 30% of Stage A HF patients during the surveyed period had blood pressure over the targets set by JNC VII and the 2014 Hypertension guidelines.[21,22] We found similar findings for patients with diabetes, another well-known risk factor for HF.[37],[38] Control of diabetes is an important predictor of new onset HF, with every 1% increase in HbA1c correlating to a 8–19% increase in HF incidence.[5–7] In addition to controlling hyperglycemia, tighter control of blood pressure is important to prevent

---

### Table 4. Socioeconomic Factors Associated with Uncontrolled Risk Factors in US Adults with Stage A HF.

| Income ≥ $20,000 | Possess Health Insurance | Education ≥ Some College |
|-------------------|--------------------------|--------------------------|
| **Prevalence Ratio, 95% CI** | **Prevalence Ratio, 95% CI** | **Prevalence Ratio, 95% CI** |
| Sodium intake ≥ 2000mg/d | 1.12 (1.07, 1.17)$ | 1.08 (0.97, 1.19) | 1.04 (1.00, 1.09) |
| | 1.10 (1.05, 1.15)$ | 1.04 (0.96, 1.14) | 1.03 (0.99, 1.07) |
| BMI ≥ 30 kg/m² | 1.04 (0.93, 1.15) | 1.12 (1.00, 1.27) | 0.91 (0.83, 1.01) |
| | 1.04 (0.93, 1.17) | 1.13 (1.00, 1.27) | 0.90 (0.82, 1.00) |
| **Persons with CHD/MI** | 0.54 (0.35, 0.84)$ | 0.48 (0.32, 0.75)$ | 0.94 (0.62, 1.43) |
| LDL ≥ 100 mg/dL | 0.58 (0.36, 0.94)‡ | 0.56 (0.34, 0.93)‡ | 1.18 (0.79, 1.75) |
| LDL ≥ 70 mg/dL | 1.08 (0.81, 1.44) | 1.15 (0.82, 1.62) | 0.99 (0.88, 1.11) |
| | 0.86 (0.73, 1.02) | 0.99 (0.88, 1.11) | 0.99 (0.88, 1.11) |
| **Persons with Diabetes** | 1.01 (0.87, 1.18) | 1.03 (0.88, 1.20) | 1.02 (0.87, 1.20) |
| HbA1c ≥ 7% | 1.03 (0.88, 1.20) | 0.89 (0.74, 1.06) | 1.01 (0.86, 1.19) |
| SBP ≥ 130 or DBP ≥ 80 mm Hg | 1.10 (0.94, 1.29) | 0.92 (0.76, 1.12) | 0.97 (0.82, 1.15) |
| | 1.13 (0.96, 1.33) | 0.99 (0.80, 1.23) | 0.93 (0.79, 1.10) |
| SBP ≥ 140 or DBP ≥ 90 mm Hg | 1.01 (0.75, 1.36) | 0.66 (0.47, 0.95)‡ | 0.90 (0.70, 1.15) |
| | 1.05 (0.77, 1.42) | 0.66 (0.46, 0.97)‡ | 0.91 (0.71, 1.18) |
| **Persons with Hypertension** | 0.91 (0.78, 1.07) | 0.95 (0.81, 1.10) | 0.96 (0.82, 1.11) |
| SBP ≥ 140 or DBP ≥ 90 mm Hg | 0.69 (0.56, 0.84)$ | 0.70 (0.56, 0.86)$ | 1.00 (0.86, 1.18) |
| | 0.95 (0.81, 1.10) | 0.96 (0.84, 1.09)$ | 0.96 (0.82, 1.11) |
| **Persons with Kidney Disease** | 1.10 (0.75, 1.61) | 1.05 (0.69, 1.60) | 1.21 (0.84, 1.73) |
| SBP ≥ 130 or DBP ≥ 80 mm Hg | 1.74 (0.85, 3.56) | 2.01 (0.93, 4.37) | 1.19 (0.85, 1.68) |
| | 2.01 (0.93, 3.56) | 2.01 (0.93, 4.37) | 1.21 (0.84, 1.73) |
| SBP ≥ 140 or DBP ≥ 90 mm Hg | 0.94 (0.47, 1.87) | 0.96 (0.42, 2.16) | 1.23 (0.78, 1.94) |
| | 2.38 (0.63, 8.97) | 2.66 (0.59, 12.08) | 1.24 (0.71, 2.17) |

*Model 1: Adjusted for age, sex, race
†Model 2: Model 1 plus adjustment for health insurance, education, income
‡P < 0.05
§P < 0.01
||Note LDL only measured in subgroup of total population, proportions are based on the total of individuals with measured values.
Abbreviations: HF, heart failure; BMI, body mass index; CHD, coronary heart disease; MI, myocardial infarction; LDL, low density lipoprotein cholesterol; HbA1c, hemoglobin A1c; SBP, systolic blood pressure; DBP, diastolic blood pressure

doi:10.1371/journal.pone.0132228.t004
HF and led to a 56% reduction in heart failure risk in those with diabetes.[8] Several studies have shown that blocking the renin-angiotensin system in persons with diabetes can decrease the incidence of HF, with losartan leading to 32–41% risk reduction.[9,10] In our population, only half of the participants with diabetes were prescribed an ACE inhibitor or ARB and only 51.6% had a HgbA1c < 7.0.

Similarly, treating CHD and lowering cholesterol are important ways to prevent the progression from Stage A to clinical HF. In people with CHD without HF, simvastatin reduces the incidence of HF after 5 years of follow-up from 10.3% to 8.3%.[11] Reduction of LDL cholesterol in stable CHD with high doses of atorvastatin was also shown to reduce heart failure hospitalizations by 26%.[12] Unfortunately, only 21% of the study participants with CHD/MI achieved an LDL <70 mg/dL, likely in part due to only 58% being on a statin. The use of ACE inhibitors after an MI reduce the incidence of HF by 39–46% in those without HF.[13–15] In those intolerant to ACE inhibitors, ARBs are considered a reasonable substitute—but the evidence for ARBs preventing HF in patients with CHD/MI is less clear.[39],[40] While not tested in Stage A HF, metoprolol succinate helps to prevent remodeling in people with Stage B HF, or asymptomatic LV dysfunction.[16] Despite the evidence for preventing HF in those with CHD/MI, only about half are prescribed ACE inhibitors/ARBs or beta-blockers.

In addition to controlling comorbid disease, the ACC guidelines include encouraging healthy lifestyle for Stage A HF. In the Physicians’ Health Study, healthy lifestyle habits including normal body weight (BMI < 25) were associated with lower lifetime risk of heart failure. [36] Compared to those with normal BMI, obese subjects had twice the risk of developing heart failure, with a graded relationship shown between BMI and HF incidence including those in the overweight category.[41] BMI also plays a role in the effect of dietary sodium on HF

| Persons prior CHD/MI | ACE inhibitor/ARB use | Statin use | Beta-blocker use | ACE inhibitor/ARB use | Statin use | Beta-blocker use |
|----------------------|----------------------|------------|-----------------|----------------------|------------|-----------------|
| Income ≥ $20k | Model 1 | Model 2 | Model 1 | Model 2 | Model 1 | Model 2 |
| 0.99 (0.76, 1.27) | 0.94 (0.72, 1.23) | 1.64 (0.87, 3.09) | 1.55 (0.79, 3.01) | 0.93 (0.73, 1.19) | 0.94 (0.73, 1.20) |
| Possess Health Insurance | | | | | | |
| Statin use | Model 1 | Model 2 | Model 1 | Model 2 | Model 1 | Model 2 |
| 1.33 (1.13, 1.56) ‡ | 1.25 (1.07, 1.46) ‡ | 1.61 (0.97, 2.66) | 1.49 (0.89, 2.47) | 1.05 (0.87, 1.26) | 1.00 (0.82, 1.23) |
| Beta-blocker use | Model 1 | Model 2 | Model 1 | Model 2 | Model 1 | Model 2 |
| 1.27 (1.00, 1.63) ‡ | 1.16 (0.88, 1.53) | 2.32 (1.22, 4.43) ‡ | 2.27 (1.09, 4.74) ‡ | 0.99 (0.81, 1.21) | 0.93 (0.77, 1.13) |

| Persons with diabetes | ACE inhibitor/ARB use | Statin use | Beta-blocker use |
|----------------------|----------------------|------------|-----------------|
| Income ≥ $20k | Model 1 | Model 2 | Model 1 | Model 2 |
| 0.99 (0.86, 1.14) | 1.00 (0.87, 1.15) | 1.07 (0.86, 1.33) | 1.04 (0.83, 1.31) | 0.90 (0.77, 1.05) | 0.92 (0.77, 1.09) |
| Possess Health Insurance | | | | | | |
| Statin use | Model 1 | Model 2 | Model 1 | Model 2 | Model 1 | Model 2 |
| 1.00 (0.97, 1.05) | 1.00 (0.97, 1.05) | 1.00 (0.97, 1.05) | 1.00 (0.97, 1.05) | 1.00 (0.97, 1.05) | 1.00 (0.97, 1.05) |
| Beta-blocker use | Model 1 | Model 2 | Model 1 | Model 2 | Model 1 | Model 2 |
| 1.00 (0.97, 1.05) | 1.00 (0.97, 1.05) | 1.00 (0.97, 1.05) | 1.00 (0.97, 1.05) | 1.00 (0.97, 1.05) | 1.00 (0.97, 1.05) |

*Model 1: adjusted for age, sex, race
†Model 2: Model 1 plus adjustment for health insurance, education, income
‡P < 0.05

Abbreviations: HF, heart failure; CHD, coronary heart disease; MI, myocardial infarction; ACE, angiotensin converting enzyme; ARB, angiotensin receptor antagonists; Statin, HMG-CoA reductase inhibitors; Beta-blocker, beta-adrenergic blocking agent

doi:10.1371/journal.pone.0132228.t005
development, with sodium intake of >2,600 mg/day compared to <1,200 mg/day associated with a 1.43 relative risk for HF in overweight subjects.

HF is an expensive disease, and requires some degree of health literacy, self-care, and access to providers to prevent hospitalizations and poor health outcomes. Lower socioeconomic status (SES) is associated with a higher risk of incidence HF by 30–50%.[42],[43] Our results suggest that control of hypertension, diabetes, and BMI is not different in lower income subjects with Stage A HF. However, lower income was associated with not being appropriately treated for CHD/MI. This corresponds to previous studies of people with CHD showing lower rates of secondary prevention and revascularization in lower SES groups.[44],[45] While education level was not associated with control of comorbid diseases or medication use in Stage A HF, health insurance was associated with control of hypertension and cholesterol as well as appropriate medication use in CHD/MI.

This study has some important limitations that warrant discussion. First, our definition of stage A HF is limited. Due to the absence of echocardiogram data, we likely include a number of participants with stage B HF. Conversely, we were unable to include adults with prior exposure to cardiotoxic medications, another subset of Stage A HF. Second, we utilize self-reported physician or health professional diagnoses to identify stage A HF. While this ensured that at least at some point both the study participant and a health provider were aware of a HF-predisposing condition, we did not include subclinical cases. By not including subclinical cases, we likely underestimate the prevalence of Stage A HF in US adults. Finally, the NHANES are cross-sectional studies. As a result, we are unable to make causal inferences.

Despite these limitations, our study has several important strengths. The complex sampling design of the NHANES minimizes selection bias, representing arguably the best available mechanism for estimating disease prevalence in the general US population.[17] This is particularly important for studies such as this, in which the focus is on the prevention of more severe disease, such as late-stage HF. Furthermore, the comprehensive and high quality data assessments allows for a thorough examination of disease prevalence, risk factors, and socioeconomic characteristics of study participants.

In conclusion, there is a high prevalence of US adults with Stage A HF, many of whom are not being appropriately or adequately treated for their risk factors. With over 75 million people at risk for developing the lethal disease HF, primary care providers and patients need to become more aware of their risk factors and aggressively treat comorbid disease to prevent progression to symptomatic HF. Additionally, more research is needed to further understand the social and contextual factors associated with achievement of national guidelines for risk factor control and medication use. Finally, HF prevention efforts should focus on aggressive, evidence-based therapy of those with multiple uncontrolled risk factors.

Supporting Information

S1 Fig. Demographic factors (age, sex, race/ethnicity) associated with poor risk factor control in US adults with stage A heart failure (HF). Examined here are lower blood pressure goals for US adults with diabetes (A) or kidney disease (B), namely a systolic blood pressure (SBP) ≥ 140 mm Hg or diastolic blood pressure (DBP) ≥ 90 mm Hg. Diamonds represent the reference groups. Circles represent the prevalence ratios. Horizontal capped lines represent the 95% confidence interval. (TIF)
Author Contributions
Conceived and designed the experiments: LCK SPJ SDR. Performed the experiments: LCK SPJ SDR. Analyzed the data: LCK SPJ SDR. Contributed reagents/materials/analysis tools: LCK SPJ SDR. Wrote the paper: LCK SPJ SDR.

References
1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013; 127: 143–152. doi: 10.1161/CIR.0b013e318282ab8f PMID: 23283859
2. Braunwald E. Heart Failure. JACC Heart Failure. 2013; 1: 1–20. doi: 10.1016/j.jchf.2012.10.002 PMID: 24621794
3. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the Impact of Heart Failure in the United States A Policy Statement From the American Heart Association. Circ Heart Fail. 2013; doi:10.1161/HHF.0b013e318291329a
4. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009; 53: e1–e90. doi:10.1016/j.jacc.2008.11.013 PMID: 19358937
5. Vaur L, Gueret P, Lievre M, Chabaud S, Passa P. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CARdiovascular Events and Ramipril) study. Diabetes Care. 2003; 26: 855–860. PMID: 12610049
6. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321: 405–412. PMID: 10938048
7. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001; 103: 2668–2673. PMID: 11390335
8. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998; 317: 703–713. PMID: 9723377
9. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861–869. doi: 10.1056/NEJMoa011161 PMID: 11565518
10. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 1004–1010. doi: 10.1016/S0140-6736(02)08090-X PMID: 11937179
11. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997; 3: 249–254. PMID: 9547437
12. Shepherd J, Kastelein JJP, Bittner V, Deedwania P, Breazza A, Dobson S, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008; 51: 1448–1454. doi: 10.1016/S0140-6736(08)60302-1 PMID: 18402899
13. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995; 332: 80–85. doi: 10.1056/NEJM199501123320203 PMID: 7990904
14. Arnold JMO, Yusuf S, Young J, Mathew J, Johnstone D, Avezum A, et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2003; 107: 1284–1290. PMID: 12628948
15. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Braun MJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327: 669–677. doi: 10.1056/NEJM199209033270101 PMID: 1366692
16. Colucci WS, Kollas TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of Ventricular
17. NHANES—National Health and Nutrition Examination Survey Homepage [Internet]. [cited 20 Feb 2013]. Available: http://www.cdc.gov/nchs/nhanes.htm

18. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation. 2010; 121: 586–613. doi: 10.1161/CIRCULATIONAHA.109.192703 PMID: 20089546

19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499–502. PMID: 4337382

20. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143–3421. PMID: 12485966

21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206–1252. doi: 10.1161/HYP.0000107251.49515.c2 PMID: 14656957

22. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311: 507–520. doi: 10.1001/jama.2013.284427 PMID: 24352797

23. Tsai J, Ford ES, Li C, Zhao G. Past and current alcohol consumption patterns and elevations in serum hepatic enzymes among US adults. Addict Behav. 2012; 37: 78–84. doi: 10.1016/j.addbeh.2011.09.002 PMID: 21975024

24. Centers for Disease Control. NHANES—NHANES 1999–2010—Manuals, Brochures, and Consent Documents [Internet]. 2010 1999 [cited 22 Nov 2011]. Available: http://www.cdc.gov/nchs/nhanes/

25. Behrens T, Taeger D, Wellmann J, Keil U. Different methods to calculate effect estimates in cross-sectional studies. A comparison between prevalence odds ratio and prevalence ratio. Methods Inf Med. 2004; 43: 505–509. doi: 10.1267/METH04050505 PMID: 15702210

26. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update Endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113: 2363–2372. doi: 10.1161/CIRCULATIONAHA.106.174516 PMID: 16702489

27. Toto RD. Treatment of Hypertension in Chronic Kidney Disease. Seminars in Nephrology. 2005; 25: 435–439. doi: 10.1016/j.semnephrol.2005.05.016 PMID: 16298269

28. Physical Activity for Everyone: The Benefits of Physical Activity | DNPAO | CDC [Internet]. [cited 10 Sep 2013]. Available: http://www.cdc.gov/physicalactivity/everyone/health/index.html#ReduceCardiovascularDisease

29. K/DOQI clinical practice guidelines on hypertension and antihypertensives agents in chronic kidney disease. American Journal of Kidney Diseases. 2004; 43, Supplement 1: S11–S13. doi: 10.1053/ajkd.2004.03.003

30. Ali MK, Bullard KM, Saadidine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med. 2013; 368: 1613–1624. doi: 10.1056/NEJMsa1213829 PMID: 23614587

31. American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013; 36 Suppl 1: S11–S66. doi: 10.2337/dc13-S011 PMID: 23264422

32. American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014; 37 Suppl 1: S14–S80. doi: 10.2337/dc14-S014 PMID: 24357209

33. Products—Data Briefs—Number 82—January 2012 [Internet]. [cited 30 Oct 2013]. Available: http://www.cdc.gov/nchs/data/databriefs/db82.htm

34. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996; 275: 1557–1562. PMID: 862246

35. Ho JE, Lyass A, Lee DS, Vasan RS, Kannel WB, Larson MG, et al. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail. 2013; 6: 279–286. doi: 10.1161/CIRCHEARTFAILURE.112.972828 PMID: 23271790

36. Djoussé L, Driver JA, Gaziano JM. Relation between modifiable lifestyle factors and lifetime risk of heart failure. JAMA. 2009; 302: 394–400. doi: 10.1001/jama.2009.1062 PMID: 19622818
37. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001; 161: 996–1002. PMID: 11295963

38. Masoudi FA, Inzucchi SE. Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol. 2007; 99: 113B–132B. doi: 10.1016/j.amjcard.2006.11.013 PMID: 17307064

39. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008 372: 1174–1183. doi: 10.1016/S0140-6736(08)61242-8 PMID: 18757085

40. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 1547–1559. doi: 10.1056/NEJMoa0801317 PMID: 18378520

41. Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002; 347: 305–313. doi: 10.1056/NEJMoa020245 PMID: 12151467

42. Hawkins NM, Jhund PS, McMurray JJV, Capewell S. Heart failure and socioeconomic status: accumulating evidence of inequality. Eur J Heart Fail. 2012; 14: 138–146. doi: 10.1093/eurjhf/hfr168 PMID: 22253454

43. Blair AS, Lloyd-Williams F, Mair FS. What do we know about socioeconomic status and congestive heart failure? A review of the literature. J Fam Pract. 2002; 51: 169. PMID: 11978216

44. Quatromoni J, Jones R. Inequalities in socio-economic status and invasive procedures for coronary heart disease: a comparison between the USA and the UK. Int J Clin Pract. 2008; 62: 1910–1919. doi: 10.1111/j.1742-1241.2008.01943.x PMID: 19166438

45. Salomaa V, Miettinen H, Niemelä M, Ketonen M, Mähönen M, Immonen-Räihä P, et al. Relation of socioeconomic position to the case fatality, prognosis and treatment of myocardial infarction events; the FINMONICA MI Register Study. J Epidemiol Community Health. 2001; 55: 475–482. PMID: 11413176